抗血管内皮生长因子治疗视盘周围脉络膜新生血管的一年结局
这项多中心回顾性介入病例系列纳入77眼(74例)初治视盘周围脉络膜新生血管膜患者,随访至少12个月,采用按需抗VEGF、光动力疗法、激光光凝或联合治疗。最佳矫正视力从基线0.55±0.54 logMAR(20/70)显著改善至12个月0.29±0.39 logMAR(20/40)(p<0.001),平均注射4.9±2.9次,黄斑中心凹厚度、黄斑下脉络膜厚度及CNV处视网膜厚度均显著降低。
要点
- 视盘周围CNVM病因多样,最常见为新生血管性年龄相关性黄斑变性、特发性、炎症性和血管样条纹。
- 12个月时最佳矫正视力从0.55±0.54 logMAR(20/70)改善至0.29±0.39 logMAR(20/40)(p<0.001)。
- 年龄(p=0.04)和基线最佳矫正视力(p<0.001)是12个月视力变化的显著预测因素。
核心结论
- 视盘周围脉络膜新生血管膜虽不常见,但与多种病因相关;抗VEGF治疗可使这类患眼在长期获得显著的视力与解剖改善,且与病因无关。
研究设计与样本
- 多中心、回顾性、介入性病例系列,纳入初治视盘周围脉络膜新生血管膜且随访至少12个月的病例,共77眼(74例患者),平均年龄61.9±21.8岁,平均病程9.2±14.1个月。
主要发现
- 最佳矫正视力从基线0.55±0.54 logMAR(20/70)显著改善至12个月0.29±0.39 logMAR(20/40)(p<0.001),平均抗VEGF注射4.9±2.9次。
- 黄斑中心凹厚度、黄斑下脉络膜厚度及CNV处视网膜厚度在12个月内均显著降低(p分别<0.001、<0.001和0.02)。
- 最常见病因为新生血管性年龄相关性黄斑变性、特发性、炎症性和血管样条纹。
- 年龄(p=0.04)和基线最佳矫正视力(p<0.001)是12个月最佳矫正视力变化的显著预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the visual and anatomical outcomes in eyes with peripapillary choroidal neovascularisation (CNV) through 12 months. METHODS: This was a multicentre, retrospective, interventional case series which included treatment-naïve cases of peripapillary choroidal neovascular membrane (CNVM) with a minimum follow-up of 12 months. Multimodal imaging which comprised optical coherence tomography (OCT), fluorescein angiography and/or indocyanine green angiography was performed at baseline and follow-up visits. OCT parameters included central macular thickness (CMT), subfoveal choroidal thickness (SFCT) and retinal and choroidal thickness at site of CNV. Patients were treated with anti-vascular endothelial growth factors (VEGF) on pro re nata protocol, photodynamic therapy, laser photocoagulation or a combination. Main outcome measures were change in best corrected visual acuity (BCVA) and OCT parameters. RESULTS: A total of 77 eyes (74 patients; mean age: 61.9±21.8 years) with a mean disease duration of 9.2±14.1 months were included. BCVA improved significantly from 0.55±0.54 logMAR (20/70) at baseline to 0.29±0.39 logMAR (20/40) at 12 months (p<0.001) with a mean of 4.9±2.9 anti-VEGF injections. CMT, SFCT and retinal thickness at site of CNVM reduced significantly (p<0.001, <0.001 and 0.02, respectively) through 12 months. The most common disease aetiologies were neovascular age-related macular degeneration, and idiopathic, inflammatory and angioid streaks. Age (p=0.04) and baseline BCVA (p<0.001) were significant predictors of change in BCVA at 12 months. CONCLUSION: Peripapillary CNVM, though uncommon, is associated with diverse aetiologies. Anti-VEGF agents lead to significant visual acuity and anatomical improvement in these eyes over long term irrespective of the aetiology.
引用
- Singh SR, Fung AT, Fraser-Bell S, et al. One-year outcomes of anti-vascular endothelial growth factor therapy in peripapillary choroidal neovascularisation. Br J Ophthalmol. 2019. PMID: 31401554. doi:10.1136/bjophthalmol-2019-314542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。